The combination treatment (palbociclib + SX-682) compared to control exhibited a normalization of the effect of SX-682 on the percentage of CD3+ T cells in the tumor (Figure 3D). The combination treatment also increased the percentage of CD3+CD8+ T cells (Figure 3E), increased the percentage of CD44+CD4+ T cells (Figure 3H), increased the percentage of CD4+CD62L+ T cells (Figure 3I), and increased the percentage of CD11b+Ly6C+ monocytes (Figure 3L) compared to control. Here, SELL is linked to neoplasm.